Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Stanford University
Kura Oncology, Inc.
Augusta University
University of Nebraska
Center for International Blood and Marrow Transplant Research
Dana-Farber Cancer Institute
Takeda
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Center for International Blood and Marrow Transplant Research
University of Colorado, Denver
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Children's Hospital of Philadelphia
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.
Thomas Jefferson University
Fred Hutchinson Cancer Center
BlossomHill Therapeutics
University of Colorado, Denver
Actinium Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Peking University People's Hospital
Celgene
Cogent Biosciences, Inc.
Celgene
Novartis
University of Chicago
University of Pittsburgh